Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Ventus to move daily oral lupus prospect into phase 2 testing
In a phase 1 study, VENT-03 “was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials," the company said.
Eric Sagonowsky
Oct 31, 2024 9:10am
GSK aims to extend lupus dominance via $300M T-cell engager deal
Oct 29, 2024 8:00am
Biogen, UCB report phase 3 lupus win after failing earlier trial
Sep 24, 2024 6:00am
CAR-T therapy for lupus nets ‘Insight’ prize for researchers
Jun 21, 2024 4:30am
Cell therapy reckoning: An unmet need remains in oncology
May 30, 2024 10:00am
How 'remarkable' results in lupus carried CAR-T to immunology
May 30, 2024 9:00am
